Objectives: To evaluate furazolidone, tetracycline and omeprazole as first line therapy for Helicobacter pylori in children with digestive symptoms.
Introduction
Helicobacter pylori infection has been associated with gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and peptic ulcer disease, and its eradication may cure gastric MALT lymphoma and prevent peptic ulcer recurrence. 1, 2 The infection is highly prevalent worldwide, mainly in developing countries. H. pylori related disease is rare in children, but most of infected patients acquire the infection at this age. Despite the fact that "test and treat" strategy is not recommended in children with abdominal pain or functional dyspepsia, if symptoms are recurrent or severe, upper gastrointestinal endoscopy with biopsies is warranted. It is controversial whether H. pylori treatment is helpful in children with functional gastrointestinal disorders, 3 but the treatment is generally indicated if the infection was diagnosed, mainly due to long-term morbidity.
Nevertheless, the best regimen for eradication therapy is an open question in children. The most used drug regimen is the Maastricht triple therapy, with clarithromycin, amoxicillin and a proton pump inhibitor, but there is an increasing prevalence of clarithromycin-resistant strains and this has produced suboptimal cure rates in children. 4, 5 Additionally, the high cost of clarithromycin impairs its generalized use in developing countries. Amoxicillin resistance is considered rare in most countries, but it is the most prescribed antibiotic for children in Brazil and up to 38% H. pylori strains have been reported to be resistant to this antibiotic in our country. 6 Metronidazole is a suitable alternative in countries with less than 40% of resistance to the drug, but in Brazil resistance to metronidazole is reported in 55% of the strains. 1, 6 Tetracyclines and furazolidone are old antimicrobial drugs, and nowadays they are not frequently prescribed in children. Thirty-six patients participated in the study, with ages ranging from 8 to 19 years old.
The study was conducted according to Good Clinical Practice and the Declaration of Helsinki, and was approved by the local ethics committees. Patients and parents were invited to participate voluntarily in the study. Parents were given a written consent form to sign, and patients were asked to verbally consent to the study protocol.
Endoscopy
The exam was performed by the authors (MRS or RSM).
Esophagus, stomach, and proximal duodenum mucosa were examined under deep sedation or general anesthesia, supervised by an anesthesiologist. Two biopsy fragments were collected from the gastric antrum at approximately 2 cm from the pylorus, one for a rapid urease test and one for histological analysis. The latter was fixed in 100 mL/L formaldehyde, placed on filter paper and stained with hematoxylin-eosin and modified Giemsa. Histological diagnosis of the infection was established by the typical appearance of the bacterium along the mucus layer covering the gastric mucous membrane. Histological evaluation was performed according to the modified Sydney system. 9 The rapid urease test was performed with a non-commercial solution (100 mg/mL aqueous urea solution with 10 mg/mL phenol red). 10 The patient was considered infected when both tests were positive and noninfected when both were negative.
H. pylori treatment
The regimen was administered for 10 days with omepra- clinically evaluated with a complete physical examination. All medicines were given to the patients, and during this examination, the patients were asked about side effects, compliance was controlled by return of empty medication blisters.
Compliance with treatment was defined as over 90% intake of the prescribed doses.
Eradication control
A second endoscopic evaluation was scheduled at least 8 weeks after the end of the treatment. During this evaluation, two biopsy fragments were collected from the gastric antrum and gastric body, one for rapid urease test and one for histological analysis. Successful treatment was defined by both rapid urease test and negative histology (gastric body and gastric antrum).
Statistical analysis
The main outcome measure was the eradication rate of the infection in intention-to-treat analysis. Sample size was estimated to be 34. The hypothesis was that the regimen would reach 90% (95%CI 80-100) success in intention-to-treat analysis. Continuous variables were expressed by calculation of mean and standard deviation. or normal gastric histology (12) .
All patients with functional abdominal pain had the H.
pylori infection eradicated, and 2/3 were asymptomatic after 2 months and 1/3 improved their symptoms. All patients with 
Discussion
The study has demonstrated tetracycline is a suitable alternative antibiotic to constitute H. pylori eradication regimens. Furazolidone has been demonstrated to be an effective drug in H. pylori treatment in Brazil, with eradication rates in adult patients up to 90% by intention to treat. 11 In children, its efficacy is lower, but it is at least similar to that exhibited by the traditional Maastricht regimen. 5, 7 Furazolidone has not been tested in conjunction with tetracycline in children, and this is the main contribution of this study. Furthermore, the triple therapy was well tolerated, with mild adverse effects.
This study is not comparative, and this is an important limitation to its generalization. It lacks comparative studies concerning the cost effectiveness of the H. pylori treatment because the studies are generally single-treatment trials with a small sample. 12 On the other hand, placebo-controlled trials are not needed to test drug regimens because the spontaneous eradication of the infection is unusual. 13 The present study was not designed as a comparative study because this regimen has never been tested in children, and it should be needed to establish the feasibility of this treatment in children. Finally, the health facilities participating in this study are not tertiary centers, which could lead to better treatment results.
Tetracycline had been the original drug in the present study, but, unfortunately, the protocol changed due to limited commercial availability. Tetracycline and doxycycline have similar costs and adverse effects. Doxycycline is almost completely absorbed, its absorption is less compromised by food and it is more bioavailable than tetracycline. It also has a longer half-life, and it can be used twice a day. 14 In a study comparing arms with tetracycline and doxycycline, both arms had similar eradication rates. 15 The main difference in antimicrobial resistance between the two drugs is that doxycycline can inhibit some tetracycline resistant Gram-positive bacteria. 16 Results suggest similar eradication rates, but there was significantly better compliance with doxycycline. On the other hand, the eradication rates were slightly higher in tet- 78.5-91). 7 These studies 5,7 had a similar study design to the present study, but they were conducted in a tertiary health facility. The eradication rate of the tetracycline-based triple therapy was slightly better in the present study, reaching 83.3% by intention-to-treat analysis and 89.7% by per protocol, and it can be attributed to the longer treatment period.
Tetracycline-based triple therapy has not yet been tested in children, and the results in this first study suggest it as a promising low-cost alternative, since it costs R$ 20.06 by patient (maximum dose, with doxycycline), against R$ 74.96 (furazolidone, clarithromycin and omeprazole, maximum dose) or R$ 70.9 (amoxicillin, clarithromycin and omeprazol, maximum dose) of the traditional regimens already tested in children in Brazil. 5, 7 Side effects cited herein were mild, but frequent (47.2%).
This is not surprising, as most of the patients had functional dyspepsia, and the adverse effect rates to the placebo Furazolidone and tetracycline therapy for H. pylori -Machado RS et al.
reported in this condition reach 37.3% in adults. 26 Side effect rates up to 34% have been reported in eradication therapy in children. 12 Previous studies with tetracycline-based regimens with adults have reported rates ranging from 34 to 59.7%, most of them mild, and the most frequent reported side effects is nausea (up to 34.6%). 18, 19, 27 It is interesting that the main side effect reported in the present study is abdominal pain, and it is likely that this symptom was related to the clinical condition of the patient rather than to the therapy.
In conclusion, tetracycline-based triple therapy is a low-cost alternative to first-line eradication therapy of the H.
pylori infection. The regimen with furazolidone, tetracycline and omeprazole is well tolerated, but comparative multicenter trials are needed to establish its role in the H. pylori infection management.
